<DOC>
	<DOC>NCT00938184</DOC>
	<brief_summary>The primary purpose of this study is to to assess the pharmacokinetics of paroxetine after single doses of paroxetine CR at the dose levels of 12.5, 25 and 50mg in healthy Japanese male volunteers.</brief_summary>
	<brief_title>Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects</brief_title>
	<detailed_description>This clinical trial is to characterize the pharmacokinetic profile after single oral doses of the proposed final market tablet formulations of paroxetine CR in Japan (the 12.5mg and 25mg tablets), at the dose levels of 12.5, 25 and 50mg in the healthy male Japanese volunteers. Treatment sequence of the 3 dose levels in each subject is randomized.</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Healthy Japanese adult males between 20 and 64 years of age inclusive BMI 18.50 or higher and &lt; 25.00 kg/m2, and bodyweight 50 kg or higher Nonsmokers AST, ALT, ALP, gammaGTP and totalbilirubin are below the upper limit of normal range QTc(B) interval &lt;450 msec Able to attend all visits and complete the study Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form Any clinically relevant abnormality on the screening physical examination, vital signs, 12lead ECG and/or clinical laboratory tests Medical history that is not considered as eligible for inclusion in this study by the investigator Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones) History of psychiatric disorder or suicide attempts or behaviours History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs History of sensitivity to any of the paroxetine formulations, or components thereof Positive for urine drug screening Participation in another clinical study or postmarketing study in which the subject is or will be exposed to an investigational or a noninvestigational product or device Participation in a clinical study or postmarketing study with an investigational or a noninvestigational product or device within 4 months of preceding the first dose of study medication History of drug or other allergy, or idiosyncrasy, excluding a pollen allergy without current symptoms History of drug abuse, or current conditions of drug abuse or alcoholism History of regular alcohol consumption exceeding, on average, 14 drinks/week (1 drink = 150 mL of wine or 350 mL of beer or 45 mL of 80 proof distilled spirits) within 6 months of screening Use of prescription or noprescription drugs, including vitamins, crude drug, herbal and dietary supplements (including St John's Wort) within 14 days prior to the first dose of study medication Unwillingness or inability to follow the procedures outlined in the protocol Consumption of grapefruit or grapefruitcontaining products from 7 days prior to the first dose of study medication Positive for syphilis, HIV antibody and antigen, Hepatitis B surface antigen, Hepatitis C antibody or HTLV1 antibody Donation of blood in excess of 400mL within the previous 4 months or 200mL within the previous 1 month to the first dose of study medication</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>tolerance</keyword>
	<keyword>single dose</keyword>
	<keyword>paroxetine</keyword>
	<keyword>controlled-release tablet</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Japanese healthy male subjects</keyword>
</DOC>